Near-infrared photothermal therapy using anti-EGFR-gold nanorod conjugates for triple negative breast cancer

Oncotarget. 2017 Sep 23;8(49):86566-86575. doi: 10.18632/oncotarget.21243. eCollection 2017 Oct 17.

Abstract

Current EGFR-targeted therapy for triple negative breast cancer (TNBC) has produced disappointing results. A rational therapeutic strategy to improve EGFR-targeted treatment for TNBC is therefore needed. In this study we evaluated the feasibility of treating TNBC using photoacoustic imaging (PAI)-guided near-infrared photothermal therapy (NIR-PTT) with anti-EGFR-conjugated gold nanorods (anti-EGFR-GN). NIR-PTT combined with anti-EGFR-GN exerted synergistic anti-proliferative and apoptotic actions through upregulation of HSP70 and cleaved caspase-3, downregulation of Ki-67 and EGFR, and inhibition of several intracellular signaling molecules (mTOR, AKT, ERK1/2 and FAK). These combined effects give this approach significant efficacy. Our findings suggest PAI-guided NIR-PTT using anti-EGFR-GN represent a novel and effective strategy for EGFR-targeted therapy in TNBC.

Keywords: breast cancer; epidermal growth factor receptor; gold nanorod; near-infrared photothermal therapy; photoacoustic imaging.